306 related articles for article (PubMed ID: 18489646)
61. Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain.
Broom R; Du H; Clemons M; Eton D; Dranitsaris G; Simmons C; Ooi W; Cella D
J Pain Symptom Manage; 2009 Aug; 38(2):244-57. PubMed ID: 19364633
[TBL] [Abstract][Full Text] [Related]
62. [A case in which alpha-interferon showed remarkable effect against the brain, bone, and lung metastases arising from the renal cell carcinoma].
Tanaka J; Takita T; Murase T; Shimoji T; Miyake K; Mitsuya H
Hinyokika Kiyo; 1986 Feb; 32(2):241-8. PubMed ID: 3728231
[TBL] [Abstract][Full Text] [Related]
63. Bisphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases.
Price N
Clin Lung Cancer; 2004 Mar; 5(5):267-9. PubMed ID: 15086964
[No Abstract] [Full Text] [Related]
64. Assessment of the impact of targeted therapy on metastatic bone disease in renal cancer.
Brown JE; Wood SL
Eur Urol; 2014 Sep; 66(3):510-1. PubMed ID: 24746971
[No Abstract] [Full Text] [Related]
65. Complete remission of bulky lung metastases of renal cell carcinoma by low-dose interferon-alpha monotherapy.
Orikasa S; Kanbe K; Minemura I
Int J Urol; 2010 Sep; 17(9):818-9. PubMed ID: 20727053
[No Abstract] [Full Text] [Related]
66. [THE PATIENTS QUALITY OF LIFE ESTlMATION IN PRESENCE OF METASTASIS OF A RENAL-CELL CANCER IN THE BONES ON BACKGROUND OF THE BISPHOSPHONATES APPLICATION].
Boychuk SI; Dedkov AG; Volkov IB; Kovahlichuk PA; Kostyuk VY
Klin Khir; 2016 Apr; (4):58-60. PubMed ID: 27434958
[TBL] [Abstract][Full Text] [Related]
67. [Encounter of cancer cells with bone. Therapy for bone metastasis from lung cancer].
Sugiura H
Clin Calcium; 2011 Mar; 21(3):439-45. PubMed ID: 21358066
[TBL] [Abstract][Full Text] [Related]
68. Bisphosphonates for care and cure.
Body JJ
Eur J Cancer; 2009 Sep; 45 Suppl 1():396-7. PubMed ID: 19775644
[No Abstract] [Full Text] [Related]
69. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma.
Kobayashi H; Tanaka Y; Shimmura H; Minato N; Tanabe K
Anticancer Res; 2010 Feb; 30(2):575-9. PubMed ID: 20332473
[TBL] [Abstract][Full Text] [Related]
70. Micro-SPET/CT and histology results of zoledronate treatment in a nude mouse lung adenocarcinoma skeletal metastases model: a pilot study.
Zhang Y; Cheng D; Shi H; Tan H; Wu B; Gu Y; Li B
Hell J Nucl Med; 2013; 16(3):240-1. PubMed ID: 24520579
[No Abstract] [Full Text] [Related]
71. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
72. Bisphosphonates as adjuvant therapy.
Shapiro CL
Clin Adv Hematol Oncol; 2009 May; 7(5):319-20. PubMed ID: 19521319
[No Abstract] [Full Text] [Related]
73. [Prolonged complete remission of multiple organ metastases after radical nephrectomy induced by interferon-alpha therapy: a case report].
Hirano A; Fujita T; Kimura T; Katoh M; Tsuji Y; Kinukawa T; Nojiri Y
Hinyokika Kiyo; 2006 Dec; 52(12):941-5. PubMed ID: 17252978
[TBL] [Abstract][Full Text] [Related]
74. Bisphosphonates and bone metastases: current status and future directions.
Krempien R; Niethammer A; Harms W; Debus J
Expert Rev Anticancer Ther; 2005 Apr; 5(2):295-305. PubMed ID: 15877526
[TBL] [Abstract][Full Text] [Related]
75. Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).
Sanders J; Crawford B; Gibson J; Joy Ho P; Iland H; Joshua D
Int J Lab Hematol; 2007 Oct; 29(5):395-7. PubMed ID: 17824924
[No Abstract] [Full Text] [Related]
76. [Effect of radiotherapy and bisphosphonate on bone metastases from renal cell carcinoma].
Okuda H; Sugiura H; Yamada K; Hayashi N; Soga N; Ogura Y
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1497-501. PubMed ID: 24231702
[TBL] [Abstract][Full Text] [Related]
77. [Progression of late metastases of renal cell carcinoma].
Wittekind C
Dtsch Med Wochenschr; 2006 Apr; 131(17):994. PubMed ID: 16673224
[No Abstract] [Full Text] [Related]
78. [PREVENTION OF THE BONES METASTASES OCCURRENCE IN THE PATIENTS WITH RENAL-CELL CANCER].
Boychuk SI; Dedkov AG; Yugrinova LG
Klin Khir; 2015 Dec; (12):44-7. PubMed ID: 27025032
[TBL] [Abstract][Full Text] [Related]
79. Characterization of bone metastases in patients with renal cell cancer.
Adiga GU; Dutcher JP; Larkin M; Garl S; Koo J
BJU Int; 2004 Jun; 93(9):1237-40. PubMed ID: 15180614
[TBL] [Abstract][Full Text] [Related]
80. Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
Amir E; Trinkaus M; Simmons CE; Dranitsaris G; Clemons MJ
J Clin Pathol; 2009 May; 62(5):474-6. PubMed ID: 19398598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
